Identifying significant trends in immunotherapy biomarkers for lung cancer enhances understanding of treatment options, leading to potential breakthroughs.
Between 2015 and 2024, 85% of publications focus on novel biomarkers related to immunotherapy in non-small cell lung cancer.
Bibliometric analysis highlights growing interest in specific immunotherapy biomarkers, emphasizing areas for further investigation and development.
Highlighting research hotspots aids in directing future studies towards impactful discoveries, fostering advancements in lung cancer treatment.